{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T12:49:54Z","timestamp":1782305394081,"version":"3.54.5"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Netherton syndrome (NS) is a rare, autosomal recessive disease resulting from a mutation in the pathogenic variants in the Kazal type 5 (SPINK5) gene. In recent years, the targeted treatment of biological agents has increasingly emerged as a focal point of research.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case reports<\/jats:title><jats:p>We reported a 4-month-old child and 19-year-old female, both presenting with symptoms including erythema, scaling, and recurring episodes. Subsequently, genetic testing identified a defective SPINK5 gene, leading to a diagnosis of NS. The child received treatment with dupilumab, while the 19-year-old woman alternated between using dupilumab and secukinumab. Both patients had swift and enduring enhancement of skin lesions during the follow-up period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>NS is an uncommon and frequently misdiagnosed hereditary dermatological disease. The management strategies for this condition are diverse, and no consensus exists. We implemented various biologic regimens for distinct patients, all demonstrating favorable outcomes and satisfactory tolerance. Besides, monitoring and evaluating the long-term safety of biologics in combination is essential.<\/jats:p><\/jats:sec>","DOI":"10.3389\/falgy.2025.1667357","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T10:28:22Z","timestamp":1756895302000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical characteristics of Netherton syndrome and exploration of targeted biologic therapy: two case reports"],"prefix":"10.3389","volume":"6","author":[{"given":"Wanyan","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengxiang","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuju","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jdcr.2017.07.019","article-title":"Infliximab therapy for Netherton syndrome: a case report","author":"Roda","year":"2017","journal-title":"JAAD Case Rep"},{"key":"B2","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00441-013-1558-1","article-title":"Netherton syndrome: skin inflammation and allergy by loss of protease inhibition","volume":"351","author":"Hovnanian","year":"2013","journal-title":"Cell Tissue Res"},{"key":"B3","first-page":"13030\/qt7m95t6v6","article-title":"Netherton syndrome with ichthyosis linearis circumflexa and trichorrhexis invaginatum","volume":"20","author":"Ng","year":"2014","journal-title":"Dermatol Online J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1001\/archderm.1964.01590250052010","article-title":"Netherton\u2019s disease; trichorrhexis invaginata (bamboo hair), congenital ichthyosiform erythroderma and the atopic diathesis. A histopathologic study","volume":"89","author":"Wilkinson","year":"1964","journal-title":"Arch Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s40291-016-0243-y","article-title":"Netherton syndrome: a genotype-phenotype review","volume":"21","author":"Sarri","year":"2017","journal-title":"Mol Diagn Ther"},{"key":"B6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/ajd.14197","article-title":"Biologics for inherited disorders of keratinisation: a systematic review","volume":"65","author":"Chen","year":"2024","journal-title":"Australas J Dermatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jid.2023.11.004","article-title":"Emerging role of the IL-36\/IL-36R axis in multiple inflammatory skin diseases","volume":"144","author":"Ahmad","year":"2024","journal-title":"J Invest Dermatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/j.1365-4632.2005.02637.x","article-title":"Netherton syndrome: a case report and review of the literature","volume":"45","author":"Sun","year":"2006","journal-title":"Int J Dermatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/bjd.19265","article-title":"The challenging management of a series of 43 infants with Netherton syndrome: unexpected complications and novel mutations","volume":"184","author":"Bellon","year":"2021","journal-title":"Br J Dermatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1038\/jid.2011.124","article-title":"Infliximab infusions for Netherton syndrome: sustained clinical improvement correlates with a reduction of thymic stromal lymphopoietin levels in the skin","volume":"131","author":"Fontao","year":"2011","journal-title":"J Invest Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3109\/08923973.2015.1115518","article-title":"A case of Netherton syndrome: successful treatment with omalizumab and pulse prednisolone and its effects on cytokines and immunoglobulin levels","volume":"38","author":"Yalcin","year":"2016","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1001\/jamadermatol.2020.1019","article-title":"Secukinumab therapy for Netherton syndrome","volume":"156","author":"Luchsinger","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2447883","DOI":"10.1080\/09546634.2024.2447883","article-title":"Abrocitinib alleviates the symptoms of Netherton syndrome and is well tolerated","volume":"36","author":"Tang","year":"2025","journal-title":"J Dermatolog Treat"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/ced\/llad242","article-title":"Treatment of Netherton syndrome with upadacitinib","volume":"48","author":"Li","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1111\/pde.14362","article-title":"Netherton syndrome: temporary response to dupilumab","volume":"37","author":"Aktas","year":"2020","journal-title":"Pediatr Dermatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1159\/000525987","article-title":"Treatment experiences with intravenous immunoglobulins, ixekizumab, dupilumab, and anakinra in Netherton syndrome: a case series","volume":"239","author":"Ragamin","year":"2023","journal-title":"Dermatology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/j.jaad.2024.07.1513","article-title":"A combination therapy with secukinumab and dupilumab in Netherton syndrome: a prospective pilot study","volume":"91","author":"Liu","year":"2024","journal-title":"J Am Acad Dermatol"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1667357\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T10:28:23Z","timestamp":1756895303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1667357\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":17,"alternative-id":["10.3389\/falgy.2025.1667357"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2025.1667357","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,3]]},"article-number":"1667357"}}